Allergan (AGN) is a winner but it is a tough time to own drug stocks, says TheStreet's Jim Cramer Allergan has had a busy year since its tax inversion deal with Pfizer (PFE) was derailed by federal regulators. The company dumped its generic drug business on Teva Pharmaceuticals (TEVA) and management has gone on a dilutive acquisition spree that has kept downward pressure on the stock. On Aug. 11, Allergan announced it would acquire eye care company ForSight Visions. On Sept. 6, AGN cut a deal to buy Retrosense Therapeutics and then on Sept. 14, management decided to purchase Vitae Pharma. If that wasn't enough deal making, on September 20, Allergan announced it would acquire Tobira Therapeutics for an upfront payment of $28.35/share in cash, and up to $49.84/share in Contingent Value Rights.
More from Video
How quickly do we find support, is what we'll want to know now, as the correction is occurring while economic optimism builds.
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.